FCGR2A and cancer: Additionally, these antibodies were not potent inducers of NK cell killing of cancer cells (Supplemental Figure 5R), nor robust inducers of NFAT reporters via CD16 (ADC) or CD32a (antibody dependent cellular phagocytosis) in engineered Jurkat cells (Supplemental Figure 5, S and T).